Philosophical Reflections on Chinese Naturopathy against Malignant Tumours
DOI:
https://doi.org/10.56226/99Keywords:
Oncology, Healthcare Management, Cancer management, holistic health, Public HealthAbstract
How to recognize the pathogenesis of cancer and how to treat cancer? This involves the "epistemology" and "methodology" of medical philosophy. With the arrival of the global aging society, and after the Covid-19 Pandemic, cancer has become a common and frequent disease.
Western medicine mainly adopts surgery, radiotherapy, chemotherapy, targeted therapy and other "allopathic therapies" for the treatment of lung, stomach and breast cancers; however, such traumatic therapies will lead to a further decline in the immune function of the patients, and at the same time of surgery, radiotherapy and chemotherapy, a new ecological environment for the metastasis and recurrence of the cancer cells has already been created. These represent main reasons why it has been difficult to improve the survival rate of cancer patients with more than 5 years in middle and late stage lung cancer, stomach cancer and other cancers. However, patients and the financing institutions, like national health insurance systems, have to bear expensive healthcare expenses for this purpose.
Especially in developing countries, many cancer patients "become poor because of cancer", and most of the middle- and late-stage cancer patients end up with "two empty pockets".
Thus, the prevention, treatment and rehabilitation of cancer has become a public health issue of global concern and a serious social issue. This is the purpose of writing this article after analyzing the pros and cons of the current "allopathic" cancer treatment model - how to analyze the pathogenesis of cancer applying the philosophical concept of Chinese naturopathy and put forward the Chinese naturopathic "Trinity" cancer treatment model. This approach is in line with the "bio-psycho-social" healthcare model advocated by the World Health Organization, so that more cancer patients can benefit from a holistic treatment process.
References
Chen, T., Shen, H., Deng, Z., Yang, Z., Zhao, R., Wang, L., Feng, Z., Liu, C., Li, W., & Liu, Z. (2017). A Chinese herbal formula SYKT reverses doxorubicin-induced myelosuppression and cardiotoxicity by inhibiting ROS-mediated apoptosis. Molecular Medicine Reports, 15(4), 2057–2066. https://doi.org/10.3892/mmr.2017.6272
da Silva Barreto, G., Brito do Nascimento, J., Cristina Santos de Almeida, K., Carlos Marcolino Neto, J., & Lucas Ferreira Luz da Silva, S. (2024). The CRISPR therapy: A revolutionary breakthrough in genetic medicine. International Healthcare Review (online). https://doi.org/10.56226/88
Dobroski, A. U. B., Duarte, B. P. F., Tanganelli, C. B., Neto, E. M. O., Naddeo, M., Valdujo, N. S., Maluf, G., & Uyeda, M. (2025). Impact of Mutations in DNA Repair Genes in Lynch Syndrome: A Systematic Literature Review. International Healthcare Review (online). https://doi.org/10.56226/93
Fu, G., Tian, M., Wang, X., Li, Y., & Su, J. (2010). Clinical study of three-dimensional conformal radiotherapy combined with SYKT in the treatment of advanced non-small cell lung cancer. International Journal of Traditional Chinese Medicine, (1), 2.
Kenupp, M. G., Vianna, A., Uyeda, M., & Maluf, G. (2024). On Patients with Colorectal Cancer : Associations, prognosis, survival and effects of therapy performed in the intestinal microbiota. International Healthcare Review (online). https://doi.org/10.56226/83
Lü, J., Wang, G., Li, L., Hu, X., Chen, D., Zhu, G., Li, W., Zhang, H., Zhou, Z., & Yin, W. (2004). Concurrent radiotherapy and SYKT treatment for locally advanced non-small cell lung cancer. Chinese Journal of Oncology, (11), 64–67.
Marques da Silva, M., Matias Cunha, C., Aquino, C., Aquino, L., & Fernanda Pizo Ferreira, P. (2025). SBRT for Uncomplicated Bone Metastases in the Spine from Lung Cancer: A literature Review. International Healthcare Review (online). https://doi.org/10.56226/92
Moslehi, J. J., Salem, J. E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018). Increased reporting of fatal myocarditis associated with immune checkpoint inhibitors. The Lancet, 391(10124), 933. https://doi.org/10.1016/S0140-6736(18)30533-6
Song, C., & Xie, H. (2023). On Disparities in Breast Cancer Screening: An Analysis of Behavioral Risk Factor Surveillance Survey Data related to Racial/ Ethnic characteristics. International Healthcare Review (online). https://doi.org/10.56226/53
Uyeda, M. (2022). On a Global Agenda for Oncology Research: From Biomarker studies to post-genomic technologies. International Healthcare Review (online), 1(1). https://doi.org/10.56226/ihr.v1i1.9
Wang, L. (2018). Study on the radiosensitization and radioprotective mechanisms of SYKT (Doctoral dissertation, Kunming Medical University).
Wang, L., Xia, Y., Chen, T., Zeng, Y., Li, L., Hou, Y., Li, W., & Liu, Z. (2018). SYKT enhances radiosensitivity of human non-small cell lung cancer cells by increasing iNOS / NO production. Biomedicine & Pharmacotherapy, 102, 618–625. https://doi.org/10.1016/j.biopha.2018.03.017 (Retraction published in Biomed Pharmacother. 2024 Dec;181:117695. doi: 10.1016/j.biopha.2024.117695)
Zhou, H., Sun, H., Zhao, P., Zhang, R., & Deng, W. (2015). Effects of SYKT adjunctive chemoradiotherapy on myelosuppression in patients with head and neck squamous cell carcinoma. Chinese Journal of Pharmacology and Toxicology, (21), 173–176. DOI: 10.13422/j.carolcarrollnki.syfjx.2015210173.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 The Publisher
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Start-up >